Literature DB >> 382359

Pharmacologic effects in man of a potent, long-acting dopamine receptor agonist.

L Lemberger, R E Crabtree.   

Abstract

Single-dose administration of pergolide mesylate (100 to 400 micrograms) results in a dose-related inhibition of prolactin secretion which persists for more than 24 hours. During multiple-dose administration of pergolide, plasma prolactin concentrations remain markedly reduced (greater than 80 percnet) and gradually return to control levels several days after drug administration is discontinued.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 382359     DOI: 10.1126/science.382359

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  12 in total

1.  Biomolecular information analysis in neurotransmitter systems.

Authors:  S C Brooks
Journal:  Acta Biotheor       Date:  1984       Impact factor: 1.774

Review 2.  Clinical pharmacokinetics of anti-parkinsonian drugs.

Authors:  J M Cedarbaum
Journal:  Clin Pharmacokinet       Date:  1987-09       Impact factor: 6.447

3.  Interactions between domperidone and ropinirole, a novel dopamine D2-receptor agonist.

Authors:  C de Mey; D Enterling; I Meineke; S Yeulet
Journal:  Br J Clin Pharmacol       Date:  1991-10       Impact factor: 4.335

4.  Pergolide as primary therapy for macroprolactinomas.

Authors:  J J Orrego; W F Chandler; A L Barkan
Journal:  Pituitary       Date:  2000-12       Impact factor: 4.107

5.  Pergolide binds tightly to dopamine D2 short receptors and induces receptor sequestration.

Authors:  P Barbier; A Colelli; R Maggio; D Bravi; G U Corsini
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

Review 6.  Anti-parkinsonian drugs today.

Authors:  N P Quinn
Journal:  Drugs       Date:  1984-09       Impact factor: 9.546

7.  Dopamine receptor mediated inhibition by pergolide of electrically-evoked 3H-dopamine release from striatal slices of cat and rat: slight effect of ascorbate.

Authors:  J Lehmann; S Arbilla; S Z Langer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1981-08       Impact factor: 3.000

8.  Pergolide therapy in Parkinson's disease.

Authors:  P Jeanty; M Van den Kerchove; A Lowenthal; H De Bruyne
Journal:  J Neurol       Date:  1984       Impact factor: 4.849

9.  Selective and extremely long inhibition of prolactin release in man by 1-ethyl-3-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'-beta- carbonyl)-urea-diphosphate (FCE 21336).

Authors:  A E Pontiroli; G C Viberti; R Mangili; L Cammelli; A Dubini
Journal:  Br J Clin Pharmacol       Date:  1987-04       Impact factor: 4.335

10.  Reduction in size of prolactin-secreting tumours in men treated with pergolide.

Authors:  P Kendall-Taylor; K Hall; D G Johnston; R W Prescott
Journal:  Br Med J (Clin Res Ed)       Date:  1982-08-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.